Pfizer's Zoetis IPO could raise $2.2B

Closing in on its IPO for its animal health unit Zoetis, Pfizer ($PFE) on Thursday reported that it would price shares between $22 and $25 each, potentially raising $2.2 billion when it happens at the end of the month, Bloomberg reports. The company intends to offer 86.1 million shares, a 20% stake, to investors. Article


 

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.